GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Forward PE Ratio

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Forward PE Ratio : 0.00 (As of Jun. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Forward PE Ratio?

Pathfinder Cell Therapy's Forward PE Ratio for today is 0.00.

Pathfinder Cell Therapy's PE Ratio without NRI for today is 0.00.

Pathfinder Cell Therapy's PE Ratio for today is 0.00.


Pathfinder Cell Therapy Forward PE Ratio Historical Data

The historical data trend for Pathfinder Cell Therapy's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pathfinder Cell Therapy Forward PE Ratio Chart

Pathfinder Cell Therapy Annual Data
Trend
Forward PE Ratio

Pathfinder Cell Therapy Quarterly Data
Forward PE Ratio

Competitive Comparison of Pathfinder Cell Therapy's Forward PE Ratio

For the Biotechnology subindustry, Pathfinder Cell Therapy's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pathfinder Cell Therapy's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pathfinder Cell Therapy's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Pathfinder Cell Therapy's Forward PE Ratio falls into.



Pathfinder Cell Therapy Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Pathfinder Cell Therapy  (OTCPK:PFND) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Pathfinder Cell Therapy Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Traded in Other Exchanges
N/A
Address
12 Bow Street, Cambridge, MA, USA, 02138
Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
Executives
John J Alam director 130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines